Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actavis’ Investment Venture To Acquire Stake In Techpool Bio-Pharma

This article was originally published in PharmAsia News

Executive Summary

Investor firm Smart Nice, majority-owned by pharmaceutical company Actavis, will accept 20 million shares of Techpool Bio-Pharma from Guangzhou Bopu and buy another 20 million shares at 5 yuan per share. Shanghai Industrial Pharmaceutical Investment and its subsidiary Huarui Investments will decrease their equity in Techpool from 51 percent to 40.8 percent, while Smart Nice will become a strategic investor with 40 percent stake. According to sources, both companies have signed an MOU to collaborate in the areas of medical science, technology, business operation and pharmaceutical-related fields. (Click here for more - Chinese language)

You may also be interested in...



QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot

ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel